Application of giant spiny frog skin polypeptide in preparation of preparation for treating or improving ulcerative colitis

Through the inhibition of inflammatory factors and regulation of intestinal microbiota by the sphincter polypeptide of the spiny frog, the existing toxicity and limited effect of the treatment of ulcerative colitis is solved, and a safe and efficient improvement effect of ulcerative colitis is achieved.

CN118903372APending Publication Date: 2024-11-08JIMEI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410829831.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing therapeutic drugs for ulcerative colitis may have adverse reactions or long-term toxicity, and have insufficient regulatory effects on the intestinal mucosal barrier and microbiota, resulting in limited therapeutic effects.

Method used

The polypeptide of the spiny-chest frog skin is used to inhibit the production of inflammation-related cytokines, increase the expression of tight junction proteins and adherent junction proteins, regulate the composition of the intestinal microbiota, and improve the symptoms of colitis and intestinal health.

Benefits of technology

It significantly improved the symptoms of colitis in mice induced by DSS, maintained colon barrier integrity, regulated the intestinal microbiota, increased the level of short-chain fatty acids, reduced the level of inflammatory factors, and provided a safe and efficient treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004911499510000031
    Figure BDA0004911499510000031
  • Figure BDA0004911499510000041
    Figure BDA0004911499510000041
  • Figure BDA0004911499510000051
    Figure BDA0004911499510000051
Patent Text Reader

Abstract

The invention relates to application of giant spiny frog skin polypeptide in preparation of a preparation for treating or improving ulcerative colitis. The amino acid sequence of the giant spiny frog skin polypeptide is shown as SEQ ID NO: 1. The giant spiny frog skin polypeptide obviously improves the symptoms of DSS-induced mouse colitis, such as weight loss, colon shortening, splenomegaly and histopathologic change; the production of proinflammatory cytokines and the expression of inflammation-related genes are inhibited, and the mRNA level of tight junction protein and adhesion junction protein is increased, so that the integrity of the colon barrier is maintained; the giant spiny frog skin polypeptide regulates the composition of intestinal microbiota, reverses the relative abundance of harmful bacteria and beneficial bacteria, and improves the level of short-chain fatty acids. The effect of improving colitis is achieved through diet intervention of the giant spiny frog skin polypeptide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an application of a frog skin polypeptide of Rana spinosa in preparing a preparation for treating or improving ulcerative colitis. Background Art

[0002] Ulcerative colitis (UC) is a chronic intestinal inflammatory disease characterized by recurrent or protracted inflammation of the intestinal mucosa. The lesions are confined to the intestinal mucosa, usually starting from the rectum and extending to the proximal colon, and even involving the entire colon. The clinical manifestations of UC are bloody stools and diarrhea, and their severity is closely related to the extent of the lesions. The pathogenesis of UC is still unclear. Existing studies have shown that intestinal epithelial barrier defects, immune response disorders, and dysbiosis are important factors that induce inflammation and lead to colitis. Therefore, a deeper understanding of UC is needed to improve the level of treatment for UC. At present, the treatment of UC is mainly aminosalicylic acid or systemic steroid hormones, immunosuppressants and biological drugs. Although the development and use of these drugs have reduced the proportion of surgical treatment in UC patients to a certain extent, these drugs may produce adverse reactions or long-term toxicity. Therefore, there is an urgent need to develop new drugs with higher safety.

[0003] The spiny-chested frog is a precious frog species in the mountainous areas of southern China. At present, the main marketing methods in the market are catering sales and live retail. The industrial chain is simple and the product form is relatively single. During the processing, many by-products such as frog skin, frog head, frog bone, etc. will be produced. In-depth research and utilization of these by-products can not only solve the problem of resource waste, but also play a positive role in environmental protection and comprehensive product development. The peptide GFGFGGF obtained by enzymatic hydrolysis of the frog skin of the spiny-chested frog has been proven to have potential antioxidant effects in previous studies, but it is still unclear as a functional food, especially its metabolic regulation in colitis. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems in the related art to a certain extent. To this end, one object of the present invention is to provide a use of a frog skin polypeptide of Rana spinosa in preparing a preparation for treating or improving ulcerative colitis, wherein the amino acid sequence of the frog skin polypeptide is shown in SEQ ID NO: 1.

[0005] According to the use of the present invention, 3% DSS was added to drinking water to construct a colitis mouse model and the effect of Rana spinosa frog skin polypeptide on improving colitis was tested. The results showed that the intake of Rana spinosa frog skin polypeptide did not lead to poor mouse status and death, and significantly improved the symptoms of DSS-induced colitis in mice, such as weight loss, colon shortening, splenomegaly and histopathological changes; Rana spinosa frog skin polypeptide treatment inhibited the production of proinflammatory cytokines and the expression of inflammation-related genes (IL-6, IL-1β, TNF-α), and increased the mRNA levels of tight junction proteins (ZO-1, Occludin) and adhesion junction proteins (E-cadherin) to maintain the integrity of the colon barrier. At the same time, Rana spinosa frog skin polypeptide treatment regulated the composition of intestinal microbiota, reversed the relative abundance of harmful and beneficial bacteria, such as up-regulating Lachnospiraceae_NK4A136_group, Muribaculaceae and Blautia, and down-regulating the abundance of Escherichia-Shigella, Akkermansia and other genera and increasing the level of short-chain fatty acids. Therefore, dietary intervention with Rana spinosa skin polypeptides has an improving effect on colitis.

[0006] In a second aspect of the present invention, the present invention provides a drug for treating or improving ulcerative colitis, comprising a frog skin polypeptide of Rana spinosa and a pharmaceutically acceptable carrier, wherein the amino acid sequence of the frog skin polypeptide of Rana spinosa is shown in SEQ ID NO: 1.

[0007] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 is a schematic diagram of a process according to Embodiment 1 of the invention;

[0009] Figure 2 The weight changes and DAI scores of mice in each group at different times according to the embodiments of the present invention;

[0010] Figure 3 The effect of the frog skin polypeptide of Rana spinosa on the colon length and spleen index of mice according to the embodiment of the present invention;

[0011] Figure 4 The effect of the frog skin polypeptide of Rana spinosa on inflammatory factors in mouse serum and inflammation-related genes in colon tissue according to the embodiment of the present invention;

[0012] Figure 5The effect of colon tissue sections and frog skin polypeptides from Rana spinosa on the mRNA levels of tight junction proteins (Z O-1, Occludin) and adherens junction proteins (E-cadherin) in the colon according to the embodiments of the present invention;

[0013] Figure 6 The effect of the frog skin polypeptide of Rana spinosa on the composition of the intestinal microbiota of mice according to the embodiment of the present invention;

[0014] Figure 7 The effect of the frog skin polypeptide of Rana spinosa on the abundance of Lachnospiraceae_NK4A136_group, Muribaculaceae, Blautia, Escherichia-Shigella, Akkermansia and other bacterial genera in the intestine of mice according to the embodiments of the present invention;

[0015] Figure 8 The figure shows the effect of the frog skin polypeptide of Rana spinosa on the level of short-chain fatty acids in the intestinal contents of mice according to an embodiment of the present invention. DETAILED DESCRIPTION

[0016] The technical solution of the present invention is described below through specific examples. It should be understood that the one or more method steps mentioned in the present invention do not exclude the existence of other method steps before and after the combination step or the insertion of other method steps between these explicitly mentioned steps; it should also be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, and is not intended to limit the order of arrangement of each method step or to limit the scope of the present invention. The change or adjustment of the relative relationship thereof shall also be regarded as the scope of the present invention without substantially changing the technical content.

[0017] In order to better understand the above technical scheme, the exemplary embodiments of the present invention are described in more detail below. Although exemplary embodiments of the present invention are shown, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to enable the scope of the present invention to be fully communicated to those skilled in the art.

[0018] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0019] The experimental materials include: SPF grade male Kunming mice, 11±2g. The experimental animals were quality tested by Suzhou Xishan Biotechnology Co., Ltd. They were raised in a clean animal breeding room according to the standards of the Animal Experiment Center (temperature: 24°C, humidity: 60±10%, 12-hour day and night rhythm) with good ventilation, and daily feed and drinking water. Before the start of the experiment, all experimental animals were adaptively raised for one week.

[0020] The frog skin polypeptide of Rana spinosa was synthesized and tested for purity by Shanghai Shenggong Biotechnology Service Co., Ltd. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1, which is GFGFGGF, and the purity is ≥95%.

[0021] The present invention is described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and do not limit the present invention in any way.

[0022] Example 1: Rana spinosa frog skin polypeptide improves the symptoms of colitis in mice induced by sodium dextran sulfate

[0023] All mice were randomly divided into 4 groups (blank control group, model group, LP group, HP group), with 6 mice in each group. Except for specific experimental conditions, all mice were maintained with standard feed and purified water. Both the LP group and the HP group received oral administration of Rana spinosa frog skin polypeptide. From the 8th day, all groups except the blank control group were given 3% (w / v) DSS aqueous solution. The LP and HP groups continued to receive oral administration of Rana spinosa frog skin polypeptide as in the first week. Figure 1 shown.

[0024] The experimental period was 16 days, during which the diarrhea, bloody stools and behavioral activities were observed every day, and the mice were weighed and recorded daily. Weight loss, bloody stools and diarrhea are characteristics of colitis, and their severity reflects the severity of colitis. The DAI score was used to evaluate the degree of diarrhea and bloody stools in mice to reflect the severity of colitis in mice. The DAI scoring criteria are shown in Table 1.

[0025] Table 1

[0026]

[0027] like Figure 2 As shown in the figure, in the first 7 days of oral administration, the weight of all mice showed a steady increase, indicating that the frog skin polypeptide of spinous chest frog did not affect the change of mouse body weight. After 8 days of DSS modeling, the weight of mice in the M group decreased significantly on days 14-16. In contrast, the weight change of mice treated with frog skin polypeptide of spinous chest frog was relatively stable, and the weight of the LP group increased on days 14-16.

[0028] The mice were deprived of food but not water for 12 hours before sampling, weighed and blood was collected from the eyeballs. The blood samples were centrifuged (3500rpm, 10min) after standing at room temperature for 30min, and then quickly killed by dislocating the neck. Colitis can lead to shortened colon length and increased spleen index. Colon samples were collected for length measurement and a certain length was taken and stored in liquid nitrogen for further experiments. The spleen of the mouse was collected and weighed and compared with the body weight, and 100 times the result was expressed as the spleen index.

[0029] like Figure 3 As shown in the figure, the colon of mice in the M group was significantly shortened, while the shortening of the colon length of mice in the LP and HP groups was significantly inhibited. In addition, the spleen index of mice in the M group increased significantly, which was inhibited to a certain extent in the LP and HP groups.

[0030] Example 2: Rana spinosa frog skin polypeptide improves the in vivo inflammatory level of dextran sodium sulfate-induced colitis in mice

[0031] Inflammatory cytokines play a key role in the pathogenesis of UC. They regulate various aspects of the inflammatory response, and the imbalance between pro-inflammatory and anti-inflammatory factors leads to inflammation and tissue damage. Pro-inflammatory cytokines in serum play a key role in the identification of UC. The level of inflammatory factors in serum reflects the degree of inflammation in mice. The levels of inflammatory factors (IL-6, IL-1β, TNF-α) in serum were detected using Elisa kits (purchased from Hangzhou Lianke Biotechnology Co., Ltd.). Total RNA in colon tissue was extracted using Trizol reagent (purchased from Wuhan Aibotek Biotechnology Co., Ltd.), and then reverse transcribed into complementary DNA (cDNA) using Prime ScriptTM reverse transcription kit (Nanjing Vazyme Biotechnology Co., Ltd.) according to the manufacturer's instructions. Quantitative PCR was performed in QuantStudio 6Flex real-time PCR system (ABI, CA, USA) using SYBR Green PCR reagent (Nanjing Vazyme Biotechnology Co., Ltd.). Gene expression levels were calculated using the 2-ΔΔCt method, and β-Actin was used as an internal control. The primers used in this example are shown in Table 2.

[0032] Table 2

[0033]

[0034]

[0035] like Figure 4As shown in the results, compared with the control group, the levels of IL-6, IL-1β, and TNF-α in the serum of DSS-induced mice were significantly increased, indicating an inflammatory response. However, in the LP and HP treatment groups, the increase in the levels of DSS-induced inflammatory factors was observed to be inhibited. In addition, the gene expression of IL-6, IL-1β, and TNF-α in colon tissue was detected. The results showed that the gene expression of IL-6 and IL-1β in the colon tissue of mice in the M group was significantly increased, and TNF-α was also increased to a certain extent. However, the gene expression of IL-6, IL-1β, and TNF-α was inhibited in the LP and HP groups, indicating that Rana spinosa frog skin polypeptide can inhibit the expression of inflammation-related genes and thus reduce the occurrence of inflammation.

[0036] Colitis can cause colonic damage and damage the colonic barrier, leading to the persistence and aggravation of inflammation. The distal colon tissue fixed with 4% paraformaldehyde solution was paraffin-embedded and sectioned, and then stained with hematoxylin and eosin (H&E) or Alcian blue and periodic acid Schiff (AB-PAS) kit (purchased from Beijing Solebow Technology Co., Ltd.). The histopathological score of the rectum was determined according to the degree of tissue damage and inflammatory cell infiltration. The specific scoring criteria are shown in Table 3.

[0037]

[0038]

[0039] Studies have shown that the reduction of goblet cells in the colonic epithelium of UC patients will lead to a decrease in the synthesis of mucin in the mucus layer, which will increase the direct interaction between the intestinal microbiota and the intestinal epithelium, and further lead to a decrease in the synthesis of tight junction proteins (ZO-1, Occludin) and adhesion junction proteins (E-cadherin) between cells. qPCR was used to detect the mRNA levels of tight junction proteins (ZO-1, Occludin) and adhesion junction proteins (E-cadherin) in colon tissue. The primer sequences and specific methods refer to the above-mentioned gene detection methods.

[0040] like Figure 5As shown in the figure, histopathological examination of colon tissues showed that compared with the DSS-induced colitis model group, treatment with R. spinosa frog skin polypeptide reduced epithelial damage, maintained crypt structure, reduced infiltration of inflammatory cells, and significantly reduced goblet cell loss. Therefore, based on H&E staining, the histopathological scores of the LP and HP groups were significantly lower than those of the M group. At the same time, qPCR results showed that the mRNA levels of tight junction proteins (ZO-1, Occludin) and adhesion junction proteins (E-cadherin) in the M group were significantly lower than those in the blank control group, indicating that the colon barrier damage of mice in the M group was more serious. However, the expression of mRNA levels of tight junction proteins (ZO-1, Occludin) and adhesion junction proteins (E-cadherin) in the colon tissues of mice in the LP and HP groups was significantly higher than that in the M group, indicating that R. spinosa frog skin polypeptide can increase the mRNA levels of tight junction proteins (ZO-1, Occludin) and adhesion junction proteins (E-cadherin) to maintain intestinal health.

[0041] Example 3: Rana spinosa frog skin polypeptide improves intestinal microbial disturbance in dextran sodium sulfate-induced colitis in mice

[0042] There are a large number of colonizing viruses, fungi and bacteria on the surface of the intestinal mucosa, collectively known as the intestinal microbiome. Among them, the intestinal flora in the distal ileum and colon is the largest and the most diverse. Studies have shown that the metabolic function of the intestinal microbiome plays an important role in maintaining human health. The total genomic DNA extraction of the microbial community in the intestinal contents is based on Soil DNA kit (Omega Bio-tek, Norcross, GA, USA) was used according to the instructions. The quality and concentration of DNA were determined by 1.0% agarose gel electrophoresis and ND-2000 spectrophotometer (Thermo Scientific Inc., MA, USA). The hypervariable region V3-V4 of the bacterial 16S rRNA gene was amplified using 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3') in a 9700PCR thermal cycler (ABA). The purified PCR products were used to construct libraries using the NEXTFLEX Rapid DNA-Seq Kit (Waltham, MA, USA). Sequencing was performed using Illumina's MiseqPE300 (Shanghai Meiji Biopharmaceutical Technology Co., Ltd.). The sequencing data were quality controlled, and sequence alignment and operational taxonomic units (OTUs) were analyzed. The species richness, evenness, and community composition were statistically analyzed using the RDP classifier.

[0043] like Figure 6 As shown in the figure, the ace and chao indexes of mice in group M were significantly lower than those in group N, while the ace and chao indexes of mice in groups LP and HP were higher than those in group M. Similarly, the shannon and simpson indices showed consistent results. This indicates that frog skin polypeptide of spiny chest frog enhances the abundance and diversity of intestinal flora. In addition, the PCoA results showed that the main microbial components of mice in group M were separated from those in groups N, LP and HP, and the LP and HP groups were close to the N group, indicating that frog skin polypeptide of spiny chest frog improved the composition of intestinal microbiota and made it close to the intestinal microbiota of normal mice. The OTU data results showed that the LP and HP groups increased the abundance of intestinal flora in mice. The main bacterial phyla of the intestinal microbiota of mice were analyzed. The results showed that the ratio of Firmicutes to Bacteroidetes (F / B) in the intestine of mice in group M increased significantly, while the LP and HP groups restored the ratio of the two to a certain extent.

[0044] Studies have shown that the abundance of beneficial bacterial genera such as Lachnospiraceae_NK4A136_group, Muribaculaceae and Blautia in the intestines of patients with colitis is often significantly suppressed. Figure 7 As shown, oral administration of frog skin peptides from Rana spinosa can upregulate the abundance of these genera; in addition, studies have shown that upregulating the Lachnospiraceae_NK4A136_group, Muribaculaceae and Blautia genera is beneficial to the recovery of colitis. Figure 7 As shown, oral administration of frog skin peptides from spiny chest frogs can inhibit pathogenic bacteria such as Escherichia-Shigella. It is worth noting that oral administration of frog skin peptides from spiny chest frogs can inhibit the abnormally increased Akkermansia in the intestines of patients with colitis and maintain it at a relatively moderate level. The maintenance of an appropriate amount of Akkermansia in the intestine is beneficial to the recovery of colitis. These results show that frog skin peptides from spiny chest frogs can improve the composition of intestinal microbiota, reverse the relative abundance of harmful and beneficial bacteria, and thus maintain intestinal health.

[0045] The intestinal microbiota is able to produce different enzymes to break down undigested food and produce short-chain fatty acids, including acetate, propionate, isobutyrate, isovaleric acid, and valeric acid. More and more studies have shown that SCFAs are not only an important energy source for colonic epithelial cells, but also promote immunity and inhibit inflammatory responses in the intestine and other organs. Recently, SCFAs have been proposed for the treatment of IBD.

[0046] Short-chain fatty acids were detected by weighing 0.05 g of cecal contents, diluting them 1:4 with 5% phosphoric acid, and storing them at -80 °C until analysis. The samples were thawed and homogenized at 69 Hz with 1.0 mm diameter zirconium oxide / silica beads for 3 min and repeated once, and then centrifuged at 13,000 × g for 30 min at 4 °C. Subsequently, 100 μL of the supernatant was transferred to a new 1.5 mL microtube and mixed with 10 μL of 2-ethylbutyric acid (Sigma, Saint Louis, MO, USA) as an internal standard. Anhydrous ether (1:1, v / v) was added to extract the samples and centrifuged at 10,000 g at 4 °C for 15 min. The organic layer was collected in another vial for further analysis. Further analysis was performed using a gas chromatograph using an Agilent 7890B system equipped with an Agilent HP-INNOWAX (30 m × 0.25 mm ID × 0.25 μm). In the split injection, 1 μL of sample was injected with a split ratio of 5:1. The injection port and transfer line temperature were maintained at 250 °C, and the temperature program started from 100 °C, increased at 15 °C / min to 175 °C, and then increased to 220 °C at 20 °C / min and maintained for 2 min; the carrier gas was nitrogen with a flow rate of 2.0 mL / min. The concentration of SCFAs was calculated based on the relative area of ​​the internal standard.

[0047] like Figure 8 As shown in the figure, compared with the N group, the intestinal SCFAs in the DSS-treated M group mice showed a downward trend, among which acetic acid, propionic acid, n-butyric acid, isobutyric acid, n-valeric acid and isovaleric acid decreased by 38.16%, 37.59%, 29.24%, 31.52%, 12.73% and 34.20%, respectively. After administration of Rana spinosa frog skin polypeptide, the levels of acetic acid, propionic acid, n-butyric acid and n-valeric acid in the intestine of mice increased significantly, and the levels of isobutyric acid and isovaleric acid also increased to a certain extent. The increased level of short-chain fatty acids may contribute to the repair of colon damage and the maintenance of barrier integrity.

[0048] In summary, the frog skin polypeptide of the embodiment of the present invention can reduce the severity of DSS-induced colitis, including weight loss, improvement of DAI score and colon length. Frog skin polypeptide can also reduce the level of serum inflammatory factors, increase the gene expression level of tight junction proteins in the colon, and improve colon barrier dysfunction. In addition, DSS causes dysregulation of the intestinal microbiota of mice, and the intervention of frog skin polypeptide of spiny chest changes the composition of the intestinal microbiota, increases the abundance of beneficial bacteria and the number of SCFAs in the intestine. The protective effect of frog skin polypeptide of spiny chest on DSS-induced colitis in mice was confirmed, which provides a theoretical basis for the development of frog skin polypeptide of spiny chest as a potential prebiotic for the treatment of colitis.

[0049] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.

[0050] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A use of a frog skin polypeptide of Rana spinosa in preparing a preparation for treating or improving ulcerative colitis, wherein the amino acid sequence of the frog skin polypeptide of Rana spinosa is shown in SEQ ID NO:

1.

2. The use according to claim 1, characterized in that The frog skin polypeptide of Rana spinosa improves the phenomena of weight loss, high DAI score and shortened colon length in colitis induced by dextran sulfate sodium.

3. The use according to claim 1, characterized in that The Rana spinosa frog skin polypeptide inhibits the production of pro-inflammatory cytokines and the expression of inflammation-related genes.

4. The use according to claim 3, characterized in that The inflammation-related genes include IL-6, IL-1β, and TNF-α.

5. The use according to claim 1, characterized in that The frog skin polypeptide of Rana spinosa increases the mRNA levels of tight junction proteins ZO-1, Occludin and adhesion junction protein E-cadherin.

6. The use according to claim 1, characterized in that The Rana spinosa frog skin polypeptide upregulates the abundance of Lachnospiraceae_NK4A136_group, Muribaculaceae and Blautia, and downregulates the abundance of Escherichia-Shigella and Akkermansia.

7. The use according to claim 1, characterized in that The Rana spinosa frog skin polypeptide increases the level of short-chain fatty acids.

8. The use according to claim 7, characterized in that The frog skin polypeptide of Rana spinosa increases the levels of acetic acid, propionic acid, n-butyric acid, n-valeric acid, isobutyric acid and isovaleric acid in the intestine.

9. A drug for treating or improving ulcerative colitis, characterized in that: The invention comprises a frog skin polypeptide of Rana spinosa and a pharmaceutically acceptable carrier, wherein the amino acid sequence of the frog skin polypeptide of Rana spinosa is shown as SEQ ID NO: 1.